Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
The ultimate guide to hand protection in life sciences
Hand protection is rarely a one size fits all, especially in the life sciences. Whether hands...
Limit your risk, avoid waste and ensure compliance to government legislation
This paper provides an overview of the importance...
How to accelerate time to market in your research lab
Your guide to electronic lab notebooks and digital...
